Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, open-label, multicenter, 2-arm study of bosutinib administered in
combination with exemestane versus exemestane alone. This is a 2-part study consisting of a
safety lead-in phase and randomized phase 2 portion. Subjects in part 1 will receive
bosutinib and exemestane daily, and will be closely monitored for 28 days. If no safety
concerns arise, then future eligible subjects will be randomly assigned to the main phase of
the study. They will either receive bosutinib daily combined with daily exemestane, or daily
exemestane alone for a specified period of time. Subjects will be followed up for survival
after treatment discontinuation.